RxDoctor Payments Data

Thomas Haskins, MD

Family Medicine · Knoxville, TNNPI 1558303198

Payments from drug & device makers

$7,481in general payments, 2019–2025

Across 507 payments — averaging $14.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$994
  • Novo Nordisk$930
  • Amgen$774
  • GSK$647
  • Pfizer$421
  • Boehringer Ingelheim$357
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$7,37199%
  • Education$1101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,481 in reported general payments places this provider in the 85th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$161,135
Medicare patients
325
Services billed
6,312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban91$91,454
Cosentyx Sensoready (2 Pens)Secukinumab12$88,611
MounjaroTirzepatide72$76,120
JanuviaSitagliptin Phosphate45$52,257
JardianceEmpagliflozin55$50,228
OzempicSemaglutide23$42,837
XareltoRivaroxaban37$26,541
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$24,358
TrulicityDulaglutide15$23,216
LinzessLinaclotide31$20,473
MyrbetriqMirabegron21$16,379
Breo ElliptaFluticasone/Vilanterol27$14,390
Repatha SureclickEvolocumab17$13,336
ShingrixVaricella-Zoster Ge/As01b/Pf40$9,114
SymbicortBudesonide/Formoterol Fumarate13$6,396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$189$99,33687 claims
PfizerEliquis$421$91,45491 claims
Boehringer IngelheimJardiance, Tradjenta$357$56,37066 claims
MerckJanuvia$188$52,25745 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$647$47,86394 claims
Novo NordiskOzempic$930$42,83723 claims
Johnson & JohnsonXarelto$254$26,54137 claims
AbbVieLinzess, Synthroid$994$24,09894 claims
Astellas Pharma US IncMyrbetriq$71$16,37921 claims
AstraZenecaSymbicort$126$6,39613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →